Precision Oncology
Redefined
Q3 2022
Forward-Looking Statements
This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commercialize small molecule therapies, our expectations about timing and ability to commence, enroll or complete clinical studies and to obtain regulatory approvals for PRT543, PRT811, PRT1419, PRT2527, PRT3645 and other candidates in development, the ability of our product candidates to treat various cancers, the ability to discover additional suitable candidates for regulatory approval, the potential impact of the COVID-19 pandemic and the sufficiency of our cash and cash equivalents to fund our operations.
Any statements contained herein or provided orally that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by such terminology as ''believe,'' ''may,'' ''will,'' ''potentially,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''could,'' ''would,'' ''project,'' ''plan,'' ''expect'' and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. Statements, including forward-looking statements, speak only to the date they are provided (unless an earlier date is indicated).
These forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to us. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. If such assumptions do not fully materialize or prove incorrect, the events or circumstances referred to in the forward-looking statements may not occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Additional risks and uncertainties that could affect our business are included under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the three months ended June 30, 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021.
2
Prelude Therapeutics: Vision
Build a fully integrated oncology company on the foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients
3
Prelude Therapeutics: Key Reasons to Invest
Internal | Effective | Strong |
Discovery | R&D | |
Execution | ||
Engine | Approach | |
Scientists with | Seamless | Proprietary |
proven track | integration | diversified |
records | between biology | pipeline |
and chemistry |
Focused
Clinical
Development
Driving to 'go/ no go' decisions
with a sense of
urgency
Well
Capitalized
~$246M cash
- marketable securities (6/30/22)
4
Experienced Management Team: Proven Track Records
Founding member
Jane Huang M.D. | Laurent Chardonnet |
Chief Financial Officer | |
President and Chief | |
Medical Officer |
Kris Vaddi, PhD
Founder &
Chief Executive Officer
Andrew Combs, PhD | Peggy Scherle, PhD |
Executive Vice President | Chief Scientific Officer |
and Head of Chemistry |
Board of Directors
Paul Friedman, MD
CEO
Former CEO
Mardi Dier
CFO
Former CFO,
CBO
Victor Sandor, MD
Former CMO
David Bonita, MD
General Partner
Julian C. Baker
Managing Member
Baker Brothers Investments
Kris Vaddi, PhD
Founder &
Chief Executive Officer
Martin Babler
Former CEO
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Prelude Therapeutics Inc. published this content on 15 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2022 18:55:05 UTC.